Nexstim Plc · OMXHEX:NXTMH
Nexstim — Nordic Life Science Days 2017
12 slides from Nexstim's conference presentation, Sep 14, 2017
Slide 1: World leader in navigated, non-invasive brain stimulation therapy and diagnosis
World leader in navigated, non-invasive brain stimulation therapy and diagnosis Martin Jamieson| CEO & Chairman of the Board | Nexstim Plc NLS Days 2017, 14 September 2017, Malmö @NexstimOyj
Slide 2: Important information
Important information This document and the information contained herein are being presented by Nexstim Oyj Certain of the information contained herein concerning industry and market data, economic (“Nexstim” or the “Company”). In connection with any presentation or review of this trends, market pos
Slide 3: Nexstim Plc at a Glance
Nexstim Plc at a Glance ● Established in 2000 ● Pioneering Electric (e) field navigated neuro stimulation technology (eTMS) ● Experienced management and international Board ● Listed in Nasdaq First North Finland & Sweden ● Offices in Finland, US and Germany 3
Slide 4: Enhancing TMS with E Field Navigation
Enhancing TMS with E Field Navigation ● Unique E field induced modeling ● Highly accurate targetingP ● Precise dosing ● Repeatable over multiple treatment sessions ● Fully integrated system ensures quality and accuracy ● TMS ● 3D MRI visualisation and stereotactic navigation ● Proprietary E-field mo
Slide 5: Our Technology – Applications
Our Technology – Applications Technology Applications – current focus Therapy Stroke Depression Chronic pain Navigated Brain Therapy (NBT) Europe US Europe US Europe US CE marked Phase III / CE marked 510(k) CE marked - E-FIT trial filed underway Diagnostic Pre-surgical mapping – tumour resections N
Slide 6: World Leading Centers Rely on NBS Pre-Surgical Mapping
World Leading Centers Rely on NBS Pre-Surgical Mapping 6
Slide 7: NBT has potential for multiple therapeutic applications due to precise navigation
NBT® (Navigated Brain Therapy) has potential for multiple therapeutic applications due to precise navigation Stroke Rehabilitation Therapy • E-FIT supplementary Phase III trial Depression Therapy underway • CE marked • CE marked • 510(k) filed with FDA Chronic Pain Therapy • CE marked Primary focus
Slide 8: Market opportunity in stroke rehabilitation
Market opportunity in stroke rehabilitation 2015 Incidence of stroke 2015 Stroke survivors USA USA 0.8 M 6.5 M China China 15 M Europe 2.5 M (7.5 M)* Europe 1.2 M 8.0 M *Published data • Large and rapidly growing market • 50% of stroke survivors will have upper limb paralysis with few available trea
Slide 9: Supplementary E-FIT Trial to Support FDA Clearance
Supplementary E-FIT Trial to Support FDA Clearance Supplementary E-FIT trial ● 60 patients – 5 leading US centers ● FDA approved trial protocol December 2016 ● Similar results expected in the active patient group as per the NICHE study which showed a clinically meaningful NBT® response in 2/3 of pat
Slide 10: Nexstim Funding
Nexstim Funding ● Company financed until Q4 2018 ● Largely complete funding arrangement with Bracknor Investment and Finnish Innovation Fund Sitra has raised a total of EUR 12.8 million ● Only open elements in the funding are EUR 14.3 million in warrants 10
Slide 11: Nexstim Milestones
Nexstim Milestones ● Complete enrolment of E-FIT trial ● Completion of the E-FIT trial in Q2 2018 ● Depression – US commercial launch in early 2018 ● Funding to support US stroke therapy commercialisation – mid/late 2018 ● Stroke commercial launch in 2019 11
Slide 12: Thank you
Thank you @NexstimOyj